Gold soars to record high over $3,900/oz amid yen slump, US rate cut bets
LONDON - Futura Medical plc (AIM:FUM), a consumer healthcare company focused on sexual health products, will publish its interim results for the six months ended June 30, 2025, on Tuesday, September 30, the company announced Friday.
The company, which specializes in developing topically delivered gel formulations, will host an investor webinar to discuss the results at 9:30 a.m. BST on the same day via the Investor Meet Company platform.
Participants can submit questions before the event until 9:00 a.m. BST the day before or during the live presentation. The webinar is open to existing and potential shareholders.
Futura Medical’s lead product is Eroxon, an over-the-counter topical gel treatment for erectile dysfunction that helps men get an erection within ten minutes. The company has established distribution partnerships in major markets, including with Haleon in the United States and Cooper Consumer Health in Europe.
The company is also developing WSD4000, a topical treatment designed for symptoms of impaired sexual response and function in women, and Eroxon Intense.
The information was provided in a press release issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.